AUPH vs GSK vs IQV vs CRL

For growth investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger pick with 20. 4% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). GSK plc (GSK) offers the better valuation at 6. 7x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GSK plc (GSK) is the cheapest at 6.

7x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, GSK plc is actually cheaper at 10. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 34x versus GSK plc's 0. 73x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, GSK plc (GSK) delivered a total return of +52.

6%, compared to -46. 6% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: AUPH returned +511. 6% versus GSK's +62. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GSK plc (GSK) is the lower-risk stock at 0.

44β versus Charles River Laboratories International, Inc. 's 1. 44β — meaning CRL is approximately 227% more volatile than GSK relative to the S&P 500. On balance sheet safety, Aurinia Pharmaceuticals Inc. (AUPH) carries a lower debt/equity ratio of 13% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurinia Pharmaceuticals Inc.

(AUPH) is pulling ahead at 20. 4% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus 12. 6% for CRL. At the gross margin level — before operating expenses — AUPH leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 34x versus GSK plc's 0. 73x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, GSK plc (GSK) trades at 10. 4x forward P/E versus 18. 7x for Aurinia Pharmaceuticals Inc. — 8. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 25. 2% to $223. 75.

In this comparison, GSK (6.

6% yield) pays a dividend. AUPH, IQV, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, GSK plc (GSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

44), 6. 6% yield). Both have compounded well over 10 years (GSK: +62. 8%, CRL: +114. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AUPH is a small-cap high-growth stock; GSK is a mid-cap deep-value stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock. GSK pays a dividend while AUPH, IQV, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.